Epidemiology of Lung Cancer

McErlean, Aoife; Ginsberg, Michelle S.

doi:10.1053/j.ro.2011.02.002

Cited by 37 publications

(29 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…1 Non-small cell lung cancer represents more than 80% of lung cancer diagnoses and has an overall 5-year survival rate of ~16% that decreases precipitously among patients diagnosed with late stage disease. 2,3 …”

Section: Introductionmentioning

confidence: 99%

Temporal Trends in Demographics and Overall Survival of Non–Small-Cell Lung Cancer Patients at Moffitt Cancer Center from 1986 to 2008

2014

View full text Add to dashboard Cite

Background An assessment of historical trends in patient survival is important to determine the progress towards patient outcomes and to reveal where advancements must be made. The goal of this study was to assess changes in demographics and overall survival of non-small cell lung cancer (NSCLC) patients who were seen at the H. Lee Moffitt Cancer Center (MCC) and Research Institute spanning over 22 years. Methods This analysis included 4,997 NSCLC patients who were treated at the MCC over five time periods: 1986 to 1988, 1991 to 1993, 1996 to 1998, 2001 to 2003, and 2006 to 2008. Kaplan-Meier survival curves and the log-rank statistic were used to assess changes in 5-year survival rates over the five time periods and multivariable hazard ratios were estimated from Cox proportional hazards models. Results From 1986 to 2008 we observed statistically significant increases in the percentage of patients over the age of 70 years, women, never- and former smokers, and patients with stage I tumors. Over the same time period the median survival time statistically significantly increased from 1.09 years (95% CI 0.95 – 1.34, P < 0.001) to 2.27 years (2.07 – 2.46, P < 0.001) and the overall 5-year survival rate for all patients significantly increased from 14.7% to 31.1% (< 0.001). Among stage I patients the 5-year survival rate increased from 31.7% to 54.0% (P < 0.001), 13.3% to 36.0% for Stage II (P < 0.001), 10.5% to 21.7% for Stage III (P < 0.001), and 3.4% to 9.6% for Stage IV (P < 0.001). Conclusions This analysis demonstrated important temporal changes in the demographics and improvements in overall survival of NSCLC patients treated at the MCC from 1986 to 2008. The 5-year survival rates and median survival time of patients diagnosed with NSCLC has significantly improved across all stages including late stage patients.

show abstract

Section: Introductionmentioning

confidence: 99%

Temporal Trends in Demographics and Overall Survival of Non–Small-Cell Lung Cancer Patients at Moffitt Cancer Center from 1986 to 2008

2014

View full text Add to dashboard Cite

show abstract

“…Lung cancer is a major health problem all over the world, with more than 1.8 million new cases being diagnosed each year and loss of about 1.6 million of these cases [31–33]. With the NSCLC being a multifactorial disease with associated to genetic risk, lifestyle and environmental exposure risk [34], no mechanism alone can fully explain all aspects of NSCLC.…”

Section: Discussionmentioning

confidence: 99%

Effect of trail C1595T variant and gene expression on the pathogenesis of non-small cell lung cancer

Erbasoglu

Horozoglu

Ercan

et al. 2018

Libyan Journal of Medicine

View full text Add to dashboard Cite

It is known that disorders in apoptosis function play an important role in the pathogenesis of many types of cancer, including lung cancer. Tumor necrosis factor related apoptosis inducing ligand (TRAIL), a type II transmembrane protein, is a death ligand capable of inducing apoptosis by activating distinctive death receptor. Our purpose in this study is to investigate the gene polymorphisms in TRAIL molecular pathway and TRAIL gene expression levels in non-small cell lung cancer (NSCLC) patients in terms of pathogenesis and prognosis of the disease. In this study, TRAIL C1595T polymorphism was genotyped using polymerase chain reaction-restriction fragment length polymorphism analysis in 158 patients with NSCLC and 98 healthy individuals. Surgically resected tissues were examined and classified histopathologically. In addition, TRAIL gene expression levels in tumor tissue and tumor surrounding tissue samples of 48 patients with NSCLC were determined using real-time polymerase chain reaction. TRAIL gene expression levels of NSCLC patients were detected significantly 28.8 fold decrease in the tumor tissue group compared to the control group (p=0.026). When patients were compared to tumor stage, expression of TRAIL gene in advanced tumor stage was found to be significantly 7.86 fold higher than early tumor stage [p=0.028]. No significant relationship was found between NSCLC predisposition and prognostic parameters of NSCLC with TRAIL genotypes, but the frequency of TRAIL gene 1595 CT genotype was observed to be lower in the patients compared to the other genotypes, and the difference was found to be very close to statistical significance (p=0.07). It can be suggested that TRAIL may play an important role in the development of NSCLC and may be an effective prognostic factor in tumor progression.: It is known that disorders in apoptosis function play an important role in the pathogenesis of many types of cancer, including lung cancer. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), a type II transmembrane protein, is a death ligand capable of inducing apoptosis by activating distinctive death receptor. Our purpose in this study is to investigate the gene polymorphisms in TRAIL molecular pathway and TRAIL gene expression levels in non-small cell lung cancer (NSCLC) patients in terms of pathogenesis and prognosis of the disease.

show abstract

“…Non-small cell lung cancer (NSCLC) represents >80% of lung cancer diagnoses and has an overall 5-year survival rate of ~16% that decreases precipitously among patients diagnosed with late stage disease (1). Although pathologic staging is prognostic for lung cancer survival (2), there is marked variability in recurrence and survival among patients with the same stage of disease, which suggests other factors contribute to the prognosis of NSCLC.…”

Section: Introductionmentioning

confidence: 99%

TNFRSF10B polymorphisms and haplotypes associated with increased risk of death in non-small cell lung cancer

Schabath¹,

Giuliano²,

Thompson³

et al. 2013

Carcinogenesis

View full text Add to dashboard Cite

Presently, there are few validated biomarkers that can predict survival or treatment response for non-small cell lung cancer (NSCLC) and most are based on tumor markers. Biomarkers based on germ line DNA variations represent a valuable complementary strategy, which could have translational implications by subclassifying patients to tailored, patient-specific treatment. We analyzed single nucleotide polymorphisms (SNPs) in 53 inflammation-related genes among 651 NSCLC patients. Multivariable Cox proportional hazard models, adjusted for lung cancer prognostic factors, were used to assess the association of genotypes and haplotypes with overall survival. Four of the top 15 SNPs associated with survival were located in the TNF-receptor superfamily member 10b (TNFRSF10B) gene. The T-allele of the top ranked SNP (rs11785599) was associated with a 41% increased risk of death (95% confidence interval [CI] = 1.16-1.70) and the other three TNFRSF10B SNPs (rs1047275, rs4460370 and rs883429) exhibited a 35% (95% CI = 1.11-1.65), 29% (95% CI = 1.06-1.57) and 24% (95% CI = 0.99-1.54) increased risk of death, respectively. Haplotype analyses revealed that the most common risk haplotype (TCTT) was associated with a 78% (95% CI = 1.25-2.54) increased risk of death compared with the lowrisk haplotype (CGCC). When the data were stratified by treatment, the risk haplotypes exhibited statistically significantly increased risk of death among patients who had surgery only and no statistically significant effects among patients who had surgery and adjuvant chemotherapy. These data suggest that possessing one or more risk alleles in TNFRSF10B is associated with an increased risk of death. Validated germ line biomarkers may have potential important clinical implications by optimizing patient-specific treatment.

show abstract

Epidemiology of Lung Cancer

Cited by 37 publications

References 41 publications

Temporal Trends in Demographics and Overall Survival of Non–Small-Cell Lung Cancer Patients at Moffitt Cancer Center from 1986 to 2008

Temporal Trends in Demographics and Overall Survival of Non–Small-Cell Lung Cancer Patients at Moffitt Cancer Center from 1986 to 2008

Effect of trail C1595T variant and gene expression on the pathogenesis of non-small cell lung cancer

TNFRSF10B polymorphisms and haplotypes associated with increased risk of death in non-small cell lung cancer

Contact Info

Product

Resources

About